Praxis Precision Medicines Showcases Ulixacaltamide at MDS 2024

Praxis Precision Medicines Unveils Phase 3 Ulixacaltamide Program at MDS 2024

Boston, September 26, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a leading clinical-stage biopharmaceutical company, is set to showcase its groundbreaking Phase 3 clinical program for ulixacaltamide at the Movement Disorders Society (MDS) 2024 International Congress in Philadelphia, Pennsylvania, from September 27 to October 1, 2024. This initiative aims to develop a novel therapy for essential tremor (ET) in adults.

Join Praxis at the MDS 2024

Praxis invites attendees to visit booth #1008 at the Pennsylvania Convention Center and participate in their insightful presentations:

• Platform Presentation: "Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide"

  • Date: Saturday, September 28
  • Time: 1:30 – 2:30 PM ET
  • Location: Meeting Room 204C

• Poster Presentation:

  • Date: Sunday, September 29
  • Time: 1:00 – 3:00 PM ET
  • Poster #: 641
  • Location: Exhibit Hall A

Presentation materials will be accessible on the Praxis Resources page post-event.

About Ulixacaltamide

Ulixacaltamide is a highly selective small molecule inhibitor targeting T-type calcium channels, designed to mitigate abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit associated with tremor activity. It represents the most advanced program within Praxis’ Cerebrum™ platform, currently under development for essential tremor treatment.

About Praxis Precision Medicines

Praxis is a pioneering clinical-stage biopharmaceutical company leveraging genetic insights to develop therapies for central nervous system (CNS) disorders marked by neuronal excitation-inhibition imbalance. Their proprietary platforms, Cerebrum™ and Solidus™, facilitate the discovery of therapies for both rare and common neurological disorders. Praxis’ portfolio includes multiple clinical-stage product candidates across movement disorders and epilepsy. For more information, visit Praxis Medicines and follow them on Facebook, LinkedIn, Instagram, and Twitter/X.

Forward-Looking Statements

This press release contains forward-looking statements as defined by The Private Securities Litigation Reform Act of 1995. These statements reflect Praxis’ current expectations and are subject to risks and uncertainties, including clinical trial outcomes, regulatory approvals, and other factors detailed in Praxis’ Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings. Praxis disclaims any obligation to update these statements publicly.

Investor Contact:

Praxis Precision Medicines

Email: investors@praxismedicines.com

Phone: 857-702-9452